121 related articles for article (PubMed ID: 38262809)
1. Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Hamad Saied M; van Straalen JW; de Roock S; Verduyn Lunel FM; de Wit J; de Rond LGH; Van Nieuwenhove E; Vastert BJ; van Montfrans JM; van Royen-Kerkhof A; de Joode-Smink GCJ; Swart JF; Wulffraat NM; Jansen MHA
Vaccine; 2024 Feb; 42(5):1145-1153. PubMed ID: 38262809
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
Dimopoulou D; Tsolia MN; Spyridis N; Maritsi DN
Rheumatology (Oxford); 2023 Feb; 62(SI2):SI205-SI209. PubMed ID: 35788275
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
10. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
12. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
13. Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
Hamad Saied M; van Straalen JW; de Roock S; de Joode-Smink GCJ; Verduyn Lunel FM; Swart JF; Wulffraat NM; Jansen MHA
Vaccine; 2023 Aug; 41(37):5477-5482. PubMed ID: 37516575
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
[TBL] [Abstract][Full Text] [Related]
15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
[TBL] [Abstract][Full Text] [Related]
17. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases.
Yeo JG; Teh KL; Chia WN; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Poh SL; Lim AJM; Tay SH; Yaung KN; Ong XM; Leong JY; Wang LF; Albani S; Arkachaisri T
Rheumatology (Oxford); 2023 Sep; 62(9):3101-3109. PubMed ID: 36661304
[TBL] [Abstract][Full Text] [Related]
19. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A
Front Immunol; 2022; 13():1016927. PubMed ID: 36311791
[TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
